Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | Chief Research Officer | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECISION BIOSCIENCES INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 57,389 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 57,389 · Balance 57,389 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 20:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 57,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040223 · wk-form4_1780517196.xml · derivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,389 Underlying: Common Stock · 57,389 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 21:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 4,925 | $3.84 | $18,912.00 |
DisclosureSEC source: 0001628280-26-009801 · wk-form4_1771536640.xml · nonDerivative · entry 2 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,926 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on April 25, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-009801 · wk-form4_1771536640.xml · derivative · entry 4 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-009801 · wk-form4_1771536640.xml · nonDerivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on February 17, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 10,200 | $4.03 | $41,106.00 |
DisclosureSEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · nonDerivative · entry 4 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,184 F4 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on April 25, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 16,219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · nonDerivative · entry 3 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 16,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · derivative · entry 8 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,219 Underlying: Common Stock · 16,219 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F7 · derivative.expiration_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 10,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · derivative · entry 7 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,447 Underlying: Common Stock · 10,447 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F6 · derivative.expiration_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · derivative · entry 6 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F5 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 10,447 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · nonDerivative · entry 2 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-003146 · wk-form4_1769125699.xml · nonDerivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · balance_after: Includes 3,413 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a weighted average price per share of $5.74 Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-081723 · ownership.xml · derivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 00:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 154 | $4.91 | $756.14 |
DisclosureSEC source: 0000950170-25-034010 · ownership.xml · nonDerivative · entry 2 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,805 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on April 25, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 519 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034010 · ownership.xml · derivative · entry 4 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 3, 2025. F4 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 3, 2025. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034010 · ownership.xml · nonDerivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on March 3, 2025. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 22, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 10,287 | $4.79 | $49,274.73 |
DisclosureSEC source: 0000950170-25-008011 · ownership.xml · nonDerivative · entry 2 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,440 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on April 25, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 16,219 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008011 · ownership.xml · derivative · entry 6 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,438 Underlying: Common Stock · 16,219 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F6 · derivative.expiration_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 10,449 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008011 · ownership.xml · derivative · entry 5 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,894 Underlying: Common Stock · 10,449 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F5 · derivative.expiration_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008011 · ownership.xml · derivative · entry 4 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 29,168 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-008011 · ownership.xml · nonDerivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2025. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 22, 2024 Filed Aug 23, 2024 11:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 48,657 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-100021 · ownership.xml · derivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,657 Underlying: Common Stock · 48,657 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 21:12 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 50 | $11.79 | $589.50 |
DisclosureSEC source: 0000950170-24-072049 · ownership.xml · nonDerivative · entry 2 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,559 F3 · kind: The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.70 to $12.00. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 21:12 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 163 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-072049 · ownership.xml · derivative · entry 4 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on June 7, 2024. F5 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on June 7, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 21:12 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-072049 · ownership.xml · nonDerivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2024. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 08, 2024 Filed May 9, 2024 00:25 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 833 | $12.00 | $9,996.00 |
DisclosureSEC source: 0000950170-24-056139 · ownership.xml · nonDerivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,446 F1 · shares: Represents shares purchased through a definitive subscription agreement, pursuant to which the Issuer agreed to issue and sell shares of its common stock in a non-brokered private placement to certain members of its management. Read SEC document |
| May 02, 2024 Filed May 3, 2024 22:32 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 154 | $10.32 | $1,589.28 |
DisclosureSEC source: 0000950170-24-053114 · ownership.xml · nonDerivative · entry 3 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,613 F4 · kind: The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.53. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:32 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 519 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-053114 · ownership.xml · derivative · entry 5 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519 Underlying: Common Stock · 519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F6 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:32 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-053114 · ownership.xml · nonDerivative · entry 2 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting of Restricted Stock Units ("RSUs") on March 3, 2024, and subsequent settlement of such vested RSUs on May 1, 2024. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F3 · balance_after: On February 13, 2024, the Issuer effected a 1-for-30 reverse stock split. The amounts of securities herein have been adjusted to reflect the reverse stock split. Read SEC document |
| April 18, 2024 Filed Apr 23, 2024 01:12 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 31,343 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-046599 · ownership.xml · derivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,343 Underlying: Common Stock · 31,343 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 29, 2024 Filed May 3, 2024 22:32 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 1,006 | $12.42 | $12,494.52 |
DisclosureSEC source: 0000950170-24-053114 · ownership.xml · nonDerivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,248 Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 00:11 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 28,000 | $0.37 | $10,360.00 |
DisclosureSEC source: 0001209191-24-002113 · doc4.xml · nonDerivative · entry 2 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,987,269 F3 · kind: The transaction was a sell-to-cover, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The reporting person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35495 to $0.37790. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 00:11 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 75,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002113 · doc4.xml · derivative · entry 4 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,985 Underlying: Common Stock · 75,015 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. F5 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F5 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 00:11 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 75,015 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-002113 · doc4.xml · nonDerivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,015,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2024. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 5,175 | $0.39 | $2,018.25 |
DisclosureSEC source: 0001209191-23-048145 · doc4.xml · nonDerivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,940,254 F1 · kind: These shares were acquired under the Issuer's 2019 Employee Stock Purchase Plan subsequent to the Reporting Person's Form 4 filed on June 9, 2023. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 4,872 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035790 · doc4.xml · derivative · entry 3 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,872 Underlying: Common Stock · 4,872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. F3 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F3 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 4,872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-035790 · doc4.xml · nonDerivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,935,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2023. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 22:12 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 15,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016842 · doc4.xml · derivative · entry 4 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,144 Underlying: Common Stock · 15,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F3 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 22:12 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 15,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016842 · doc4.xml · nonDerivative · entry 2 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on March 3, 2023. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 28, 2023 Filed Mar 7, 2023 22:12 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 12,157 | $0.95 | $11,549.15 |
DisclosureSEC source: 0001209191-23-016842 · doc4.xml · nonDerivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,914,631 Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 225,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004611 · doc4.xml · derivative · entry 1 SMITH J. JEFFERSON · CIK 0001770169 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.